Asset Details
Do you wish to reserve the book?
The effect of interferon-beta1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The effect of interferon-beta1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis
Do you wish to request the book?
The effect of interferon-beta1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The effect of interferon-beta1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis
2007
Overview
Abstract Objectives In 85% of young adults with multiple sclerosis (MS), onset is a subacute clinically isolated syndrome (CIS) of the optic nerves, brain stem or spinal cord. The advent of disease-modifying treatments for MS has increased attention on early stages of the disease. Therefore, the aim of this study was to evaluate the effect of interferon on relapses and progression of disability in patients with a CIS. Patients and methods This randomized, clinical trial was conducted in 25 patients who presented with a CIS indicative of MS. They were evaluated in two groups: 11 patients who were receiving interferon-beta1a (Rebif, Serono) subcutaneous injections three times a week (group A), and 14 patients who were not receiving disease-modifying treatment (group B). The progression of disability was determined using the Kurtzke Expanded Disability Status Scale (EDSS) and the numbers of new relapses were recorded during 21 months of follow-up. Results The mean numbers of new relapses and changes in EDSS at the end of study period were 0.68 (standard deviation [S.D.] = 0.80) and −1.09 (S.D. = 0.49), and 1.79 (S.D. = 1.05) and −0.64 (S.D. = 0.49) in groups A and B, respectively. Statistical analysis showed that disease-modifying treatment with interferon-beta1a may reduce relapses ( P = 0.007) and prevent progressive disability ( P = 0.034). Conclusion Interferon-beta1a significantly delayed progression to disability and incidence of new relapses.
Publisher
Elsevier Science,Elsevier Limited
Subject
Adjuvants, Immunologic - therapeutic use
/ Adult
/ Biological and medical sciences
/ Brain
/ Cerebellar Diseases - diagnosis
/ Cerebellar Diseases - drug therapy
/ Drug Administration Schedule
/ Female
/ Humans
/ Interferon-beta - therapeutic use
/ Male
/ Multiple Sclerosis, Chronic Progressive - diagnosis
/ Multiple Sclerosis, Chronic Progressive - drug therapy
/ Myelitis, Transverse - diagnosis
/ Myelitis, Transverse - drug therapy
/ Neurologic Examination - drug effects
/ Optic Neuritis - drug therapy
/ Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
/ Syndrome
